Menu Search
Equities

Biodesix Inc

BDSX:NMQ

Biodesix Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.33
  • Today's Change0.05 / 3.91%
  • Shares traded629.84k
  • 1 Year change-12.50%
  • Beta1.1327
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Biodesix Inc grew revenues 28.46% from 38.21m to 49.09m while net income improved from a loss of 65.45m to a smaller loss of 52.15m.
Gross margin77.72%
Net profit margin-66.84%
Operating margin-53.33%
Return on assets-46.24%
Return on equity-331.82%
Return on investment-60.89%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Biodesix Inc fell by 16.80m. Cash Flow from Financing totalled 29.13m or 59.34% of revenues. In addition the company used 22.87m for operations while cash used for investing totalled 23.06m.
Cash flow per share-0.3334
Price/Cash flow per share--
Book value per share0.1915
Tangible book value per share0.0439
More ▼

Balance sheet in USDView more

Biodesix Inc has a Debt to Total Capital ratio of 56.47%.
Current ratio3.40
Quick ratio--
Total debt/total equity1.30
Total debt/total capital0.5647
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.